Li X M, Von Euler G, Hedlund P B, Finnman U B, Fuxe K
Department of Histology and Neurobiology, Karolinska Institutet, Stockholm, Sweden.
Eur J Pharmacol. 1993 Mar 30;234(1):125-8. doi: 10.1016/0014-2999(93)90716-u.
The effects of neurotensin fragments and of neurotensin itself on the characteristics of neostriatal dopamine D2 agonist binding were studied in competition experiments with dopamine using the D2 antagonist, [3H]raclopride. The biologically active neurotensin-(8-13) fragment, but not the inactive neurotensin-(1-7) fragment, caused a concentration-related increase in the KH and KL values of dopamine with a maximal increase by 110 and 97%, respectively, at 1 nM, while neurotensin-(1-13) only induced such changes at 10 nM. In view of the higher potency and the increased ability of neurotensin-(8-13) versus neurotensin (1-13) to reduce the affinities of the high- and low-affinity states of the neostriatal D2 receptors, the C-terminal neurotensin fragments may be among the endogenous ligands of the neostriatal neurotensin receptors.
使用D2拮抗剂[3H]雷氯必利,在与多巴胺的竞争实验中研究了神经降压素片段及其本身对新纹状体多巴胺D2激动剂结合特性的影响。具有生物活性的神经降压素-(8-13)片段而非无活性的神经降压素-(1-7)片段,导致多巴胺的KH和KL值呈浓度依赖性增加,在1 nM时分别最大增加110%和97%,而神经降压素-(1-13)仅在10 nM时诱导此类变化。鉴于神经降压素-(8-13)相对于神经降压素(1-13)具有更高的效力以及更强的降低新纹状体D2受体高亲和力和低亲和力状态亲和力的能力,C末端神经降压素片段可能是新纹状体神经降压素受体的内源性配体之一。